Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts

This is a multi-center study to investigate the impact of fibrotic liver greafts in liver transplant recipient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Transplant

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhejiang University school of Medicine

Hangzhou, Zhejiang, 310006, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients receiving liver transplantation during the period from March 2015 to March 2024

Exclusion criteria

recipients under 18 years old
re-transplantation cases
multiorgan transplant cases, reduced-size or split LT cases
lacking follow-up records or graft biopsy records

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

Overall survival rates

Time frame: January 2015 to December 2024

The overall survival of liver transplant recipients.

Secondary outcomes

Graft survival rates

Time frame: January 2015 to December 2024

The graft survival of liver transplant recipients.

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Registry information

Official study title

Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts: a Retrospective Cohort Analysis of the US National Database

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Aug 3, 2025
Registry last updated: Aug 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed